register

News & Trends - MedTech & Diagnostics

Competition watchdog raises concerns over cancer care provider’s expansion plans

Health Industry Hub | June 14, 2024 |

MedTech & Diagnostics News: A leading provider of cancer care services in Australia, faces scrutiny from the Australian Competition and Consumer Commission (ACCC) over its proposed acquisitions of leases at St Andrew’s Ipswich Private Hospital and St Vincent’s Private Hospital Northside in Queensland, as well as St John of God Geelong Hospital in Victoria.

Currently, Icon and GenesisCare dominate the private radiation oncology market in Australia, controlling 94% of all clinics. The next largest provider, Cancer Care Associates, operates only four clinics in New South Wales.

“We are concerned that the proposed acquisition will entrench Icon’s already strong market position, which may increase its ability to raise the prices it charges or reduce the level of service it provides patients,” said ACCC Commissioner Stephen Ridgeway.

The ACCC’s Statement of Issues highlights potential impacts on the supply of radiation oncology services in the greater Geelong and Brisbane areas. The ACCC is also examining potential effects in broader regions, such as south-east Queensland.

“We are concerned that Icon’s plans to enter into new lease arrangements in South-East Queensland and Geelong may increase barriers to entry or expansion for new and existing providers,” Ridgeway added.

He noted the limited number of specialists in Australia, suggesting Icon’s expansion could restrict competitors’ ability to attract and retain necessary medical professionals.

In Ipswich, there are currently no radiation oncology providers, with the nearest facility approximately a 30-minute drive away. In Geelong, Icon operates the only private radiation oncology clinic. Brisbane has six private clinics, four operated by Icon and two by GenesisCare.

The ACCC is investigating whether Icon’s proposed acquisitions would leverage economies of scale and scope, potentially insulating the company from competition. This includes increased utilisation of specialists, staff, and equipment at multiple clinics.

“An acquisition enabling Icon to expand its radiation oncology services is concerning if it insulates Icon from competition,” Ridgeway stated.

Submissions should be emailed to mergers@accc.gov.au by 20 June 2024.

In reimagining healthcare, Health Industry HubTM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.

The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.


ESG

Surgeons lead push for $1.5 million hospital sustainability project

Surgeons lead push for $1.5 million hospital sustainability project

Health Industry Hub | October 23, 2024 |

ESG: Australia’s healthcare sector contributes 7% of the country’s total emissions. The Royal Australasian College of Surgeons (RACS) has joined […]

More


News & Trends - MedTech & Diagnostics

AI-assisted colonoscopy boosts polyp and adenoma detection

AI-assisted colonoscopy boosts polyp and adenoma detection

Health Industry Hub | October 23, 2024 |

MedTech & Diagnostics News: In a standard colonoscopy, as many as one-third of colorectal polyps and adenomas can go by […]

More


News & Trends - Pharmaceuticals

'Every day of delay is costing Australian lives', says Rare Cancers Australia CEO

‘Every day of delay is costing Australian lives’, says Rare Cancers Australia CEO

Health Industry Hub | October 23, 2024 |

Pharma News: Rare Cancers Australia (RCA) has voiced its disappointment alongside the pharmaceutical industry following the Pharmaceutical Benefits Advisory Committee’s […]

More


News & Trends - Pharmaceuticals

Government's silence on Senate report leaves cancer patients in limbo

Government’s silence on Senate report leaves cancer patients in limbo

Health Industry Hub | October 23, 2024 |

Pharma News: NeuroEndocrine Cancer Australia has urged the government to respond to the Senate report on equitable access to diagnosis […]

More


This content is copyright protected. Please subscribe to gain access.